A decision aid for patients with kidney tumors
Evaluation of a Decision Aid in the Treatment Planning of Small Renal Tumors
This study is testing a new online tool to help patients with kidney tumors make better treatment choices based on what matters most to them.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05387863 on ClinicalTrials.gov |
What this trial studies
This study aims to understand how patients make treatment decisions regarding their kidney masses by identifying their key values and preferences. The research team will develop a decision aid (DA) web tool that utilizes a decision-analytic model to communicate personalized benefit and harm estimates to patients. This approach promotes patient-centered treatment options for renal tumors, enhancing the decision-making process for individuals facing these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are male and female patients aged 18 and older who have been diagnosed with a localized renal tumor up to 4 cm in diameter and are scheduled for standard clinical exams.
Not a fit: Patients with stage IV cancer or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this could empower patients with kidney tumors to make more informed treatment decisions tailored to their personal values and preferences.
How similar studies have performed: While the specific approach of using a decision aid for renal patients may be novel, similar studies in other areas have shown success in improving patient decision-making.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter. * Patients scheduled for standard-of-care clinical exams with the NYU Urology Department Exclusion Criteria: * Stage IV cancer of any type * Inability to provide informed consent * Vulnerable subjects will not be recruited
Where this trial is running
New York, New York
- NYU Langone Health — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Stella Kang, MD — NYU Langone Health
- Study coordinator: Stella Kang, MD
- Email: Stella.kang@nyulangone.org
- Phone: 212-263-6246
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.